Cadrenal Therapeutics Inc (CVKD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.22-4.69%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CVKD
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | |
|---|---|---|---|---|---|
| Revenues | |||||
| Cost of Revenues | — | — | — | 0.2 | — |
| Operating Expenses & Income | |||||
| R&D Expenses | 2.8 | 4.1 | 4.2 | 4.1 | 0.4 |
| Operating Income | (11.7) | (13.5) | (11.0) | (7.6) | (2.7) |
| Earnings from Continuing Operations | |||||
| Interest Expense | — | — | — | — | 0.0 |
| Other Non-Operating Income / Expenses | 0.1 | 0.2 | 0.3 | (0.7) | (4.0) |
| Net Income | |||||
| Net Income | (11.5) | (13.2) | (10.7) | (8.4) | (6.7) |
| Per Share | |||||
| Basic EPS | (3.96) | (6.64) | (8.73) | (9.29) | (0.85) |
| Diluted EPS | (3.96) | (6.64) | (8.73) | (9.29) | (0.85) |
| Dividend per Share | — | 16.50 | 16.50 | — | — |
| Basic Weighted Avg Shares | 2.9 | 2.0 | 1.2 | 0.9 | 7.9 |
| Diluted Weighted Avg Shares | 2.9 | 2.0 | 1.2 | 0.9 | 7.9 |
| Supplemental | |||||
| EBIT | (11.7) | (13.5) | (11.0) | (7.6) | (2.7) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.